GlassScriptPhysician profile
Eric S Lee
NPI 1649564410
$3,367.58
in general payments reported to CMS, 2019-2025
21 companies · $693 in 2025
The $693 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $317 · 2021: $288 · 2022: $359 · 2023: $560 · 2024: $892 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.93 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $679.38 | 2022-2025 | Eterna, Proclaim |
| Janssen Biotech, INC. | $524.98 | 2021-2025 | Tremfya, Erleada, Balversa |
| Abbvie INC. | $371.16 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $235.23 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $233.29 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Amgen INC. | $204.76 | 2020-2025 | Otezla |
| Leo Pharma INC. | $159.79 | 2019-2022 | |
| Pfizer INC. | $131.11 | 2020-2024 | |
| Arcutis Biotherapeutics, INC. | $127.74 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $108.02 | 2023-2024 | Vtama |
| Genzyme Corporation | $103.24 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $82.48 | 2022-2025 | Sotyktu |
| Incyte Corporation | $66.63 | 2021-2022 | |
| Novo Nordisk INC | $65.86 | 2019 | |
| Galderma Laboratories, L.P. | $56.09 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.40 | 2023 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $42.89 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $41.68 | 2025 | Tecnis Iol |
| Dermira, INC. | $32.67 | 2019 | |
| Ucb, INC. | $30.16 | 2023 | Cimzia |
| Almirall LLC | $17.02 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.